POLE and endometrial carcinoma: The present study aimed to: (1) resolve the reported clinicopathology variations of POLE-mutant endometrial carcinoma and confirm (2) the prognostic benefit of the POLE (exonuclease domain mutant) subtype using survival analysis of the expanded cohort of studies.